Maria Hashme
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Hashme has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- M. Firouz Mohd Mustapa
British Association of Dermatologists , Willan House, London
6 shared publications - Alina M Constantin
British Association of Dermatologists , Willan House, London
4 shared publications - Andrew Robert Thompson
Doctoral Programme in Clinical Psychology, Cardiff & Vale University Health Board & School of Psychology, Cardiff University , Cardiff, Wales
3 shared publications - Abby E. Macbeth
Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK
2 shared publications - Ali S. M. Jawad
Royal London Hospital London UK
2 shared publications Amy Johnson
Patient representative
2 shared publications
Latest Publications
- 22 October 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
British Association of Dermatologists guideline for managing fungal nail infection (onychomycosis) 2026
Lay Summary: Fungal nail infection (FNI) is a common condition. It affects the toenails and fingernails. Fungi grow in the nail, causing thickening, discoloration or crumbling. Around 1 in 2000 children have FNI. This increases to one in three people aged over 65 years. The British Association of Dermatologists brought together a group of experts on FNI. They included consultant dermatologists, pharmacists, podiatrists and people with lived experience of FNI. The group reviewed the published evidence on treatment. This UK-based group produced 44 recommendations. Management of most people with FNI is in primary care. However, more complex cases may need referral to a dermatologist. Accurate diagnosis is important. Treatment decisions should always fit the person with FNI. Factors include the type of infection, age, general health and personal preference. People with FNI should be told the benefits and risks of treatment and how long treatment will take. Nails may not always return to their previous appearance even when the infection is cured. Topical treatments are those applied to the affected nail. These may be suitable for mild infections or for people who cannot take oral medication. For many, an oral tablet called ‘terbinafine’ is the first-line treatment. When terbinafine is not suitable, other oral tablets called ‘itraconazole’ or ‘fluconazole’ can be used. Combination approaches may be helpful for stubborn infections. Children and young people can receive antifungal medicines. Doses should be adjusted according to their age and weight. The authors present a management pathway for patients with FNI. This will guide clinicians through the treatment options. Recommendations for future research are also included. Finally, audit points are presented. These will allow hospitals to check that the care of patients with FNI is meeting the right standards.
- 22 October 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
British Association of Dermatologists guideline for managing fungal nail infection (onychomycosis) 2026
Lay Summary: Fungal nail infection (FNI) is a common condition. It affects the toenails and fingernails. Fungi grow in the nail, causing thickening, discoloration or crumbling. Around 1 in 2000 children have FNI. This increases to one in three people aged over 65 years. The British Association of Dermatologists brought together a group of experts on FNI. They included consultant dermatologists, pharmacists, podiatrists and people with lived experience of FNI. The group reviewed the published evidence on treatment. This UK-based group produced 44 recommendations. Management of most people with FNI is in primary care. However, more complex cases may need referral to a dermatologist. Accurate diagnosis is important. Treatment decisions should always fit the person with FNI. Factors include the type of infection, age, general health and personal preference. People with FNI should be told the benefits and risks of treatment and how long treatment will take. Nails may not always return to their previous appearance even when the infection is cured. Topical treatments are those applied to the affected nail. These may be suitable for mild infections or for people who cannot take oral medication. For many, an oral tablet called ‘terbinafine’ is the first-line treatment. When terbinafine is not suitable, other oral tablets called ‘itraconazole’ or ‘fluconazole’ can be used. Combination approaches may be helpful for stubborn infections. Children and young people can receive antifungal medicines. Doses should be adjusted according to their age and weight. The authors present a management pathway for patients with FNI. This will guide clinicians through the treatment options. Recommendations for future research are also included. Finally, audit points are presented. These will allow hospitals to check that the care of patients with FNI is meeting the right standards.
- Open Access
- 5 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1035-1045
British Association of Dermatologists living guideline for managing people with nodular prurigo (prurigo nodularis) 2025
Lay Summary: Nodular prurigo (NP) is a chronic skin condition. Lesions can be either single or widespread on the body. Thus, it can have a negative impact on a person’s quality of life. The exact cause of NP is unknown, as several mechanisms play a role. These mechanisms sometimes overlap between physical and brain–behavioural elements. Dermatologists diagnose NP based on a history of long-lasting itching and scratching. A Guideline Development Group met to produce a new guideline for treating people with NP. The group included consultant dermatologists, a psychotherapist, dermatology trainees, a general practitioner and people with lived experience of NP. The group identified and reviewed the current literature on treating NP. They discussed the findings at length before producing a set of recommendations. The guideline will provide up-to-date management guidance for healthcare practitioners. Initial steps included taking a full history and examination of patients. This included causes of itch, patient education and reversing the itch–scratch habit. The first treatment option is usually topical therapy (applied to the skin). If this fails, other options include phototherapy and oral medications. Further treatments include nonsedating antihistamines and low-dose antidepressants. Steroid injections or cryotherapy (freezing with liquid nitrogen) are options for single lesions. The guideline provides recommendations for treating people with NP. It also includes recommendations for future research and audit points for hospitals. A patient information leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/nodular-prurigo).
- 5 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1035-1045
Open AccessBritish Association of Dermatologists living guideline for managing people with nodular prurigo (prurigo nodularis) 2025
Lay Summary: Nodular prurigo (NP) is a chronic skin condition. Lesions can be either single or widespread on the body. Thus, it can have a negative impact on a person’s quality of life. The exact cause of NP is unknown, as several mechanisms play a role. These mechanisms sometimes overlap between physical and brain–behavioural elements. Dermatologists diagnose NP based on a history of long-lasting itching and scratching. A Guideline Development Group met to produce a new guideline for treating people with NP. The group included consultant dermatologists, a psychotherapist, dermatology trainees, a general practitioner and people with lived experience of NP. The group identified and reviewed the current literature on treating NP. They discussed the findings at length before producing a set of recommendations. The guideline will provide up-to-date management guidance for healthcare practitioners. Initial steps included taking a full history and examination of patients. This included causes of itch, patient education and reversing the itch–scratch habit. The first treatment option is usually topical therapy (applied to the skin). If this fails, other options include phototherapy and oral medications. Further treatments include nonsedating antihistamines and low-dose antidepressants. Steroid injections or cryotherapy (freezing with liquid nitrogen) are options for single lesions. The guideline provides recommendations for treating people with NP. It also includes recommendations for future research and audit points for hospitals. A patient information leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/nodular-prurigo).
- 14 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (2) , e56-e73
British Association of Dermatologists living guideline for managing people with alopecia areata 2025
Lay Summary: Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Alopecia totalis is the name for total loss of scalp hair. Alopecia universalis is complete loss of scalp, facial and body hair. This is the second version of the guideline. The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of eight consultant dermatologists, one dermatology specialist registrar, one general practitioner, one psychologist, two people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 11 July 2025. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 56 recommendations for management of people with AA. They also made 9 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, a patient information leaflet is also available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).
- 14 November 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (2) , e56-e73
British Association of Dermatologists living guideline for managing people with alopecia areata 2025
Lay Summary: Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Alopecia totalis is the name for total loss of scalp hair. Alopecia universalis is complete loss of scalp, facial and body hair. This is the second version of the guideline. The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of eight consultant dermatologists, one dermatology specialist registrar, one general practitioner, one psychologist, two people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 11 July 2025. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 56 recommendations for management of people with AA. They also made 9 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, a patient information leaflet is also available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).
- 29 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , e1-e19
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025
The overall objective of this living guideline with a fixed-interval schedule is to provide up-to-date, evidence-based recommendations for the management of Behçets disease/syndrome in adults, children and young people. The literature will be reviewed at least every 6 months, with a living guideline updating cycle of 12 months. The current iteration aims to: (i) offer an appraisal of all relevant literature up to 23 May 2025 focusing on any key developments; (ii) address important, practical clinical questions relating to the primary guideline objective; and (iii) provide guideline recommendations and appropriate research recommendations.
- 29 September 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (1) , e1-e19
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025
The overall objective of this living guideline with a fixed-interval schedule is to provide up-to-date, evidence-based recommendations for the management of Behçets disease/syndrome in adults, children and young people. The literature will be reviewed at least every 6 months, with a living guideline updating cycle of 12 months. The current iteration aims to: (i) offer an appraisal of all relevant literature up to 23 May 2025 focusing on any key developments; (ii) address important, practical clinical questions relating to the primary guideline objective; and (iii) provide guideline recommendations and appropriate research recommendations.
- Open Access
- 21 October 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (2) , 190-205
British Association of Dermatologists living guideline for managing people with alopecia areata 2024
Lay Summary: Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Total loss of scalp hair is called alopecia totalis (AT). Complete loss of scalp, facial and body hair is called alopecia universalis (AU). The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of 11 dermatologists, 1 psychologist, 2 people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 19 October 2023. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 49 recommendations for management of people with AA. They also made 7 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, the group prepared an updated patient information leaflet. The leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).
- 21 October 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (2) , 190-205
Open AccessBritish Association of Dermatologists living guideline for managing people with alopecia areata 2024
Lay Summary: Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Total loss of scalp hair is called alopecia totalis (AT). Complete loss of scalp, facial and body hair is called alopecia universalis (AU). The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of 11 dermatologists, 1 psychologist, 2 people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 19 October 2023. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 49 recommendations for management of people with AA. They also made 7 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, the group prepared an updated patient information leaflet. The leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).
- Open Access
- 10 September 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (5) , e8-e25
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of Behçets. The document aims to offer an appraisal of all relevant literature up to 25 August 2023 focusing on any key developments; to address important, practical clinical questions relating to the primary guideline objective; and to provide guideline recommendations and appropriate research recommendations.
- 10 September 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (5) , e8-e25
Open AccessBritish Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of Behçets. The document aims to offer an appraisal of all relevant literature up to 25 August 2023 focusing on any key developments; to address important, practical clinical questions relating to the primary guideline objective; and to provide guideline recommendations and appropriate research recommendations.